Journal article
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer
Abstract
BACKGROUND: A phase 2 trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer led to an objective response in approximately 30% of patients and a median survival of 14 months. In the current study, the authors report further efficacy data of a larger cohort of such patients treated with the GemCap regimen.
METHODS: Patients aged >18 years and who had a diagnosis of locally advanced biliary cancer received …
Authors
Riechelmann RP; Townsley CA; Chin SN; Pond GR; Knox JJ
Journal
Cancer, Vol. 110, No. 6, pp. 1307–1312
Publisher
Wiley
Publication Date
September 15, 2007
DOI
10.1002/cncr.22902
ISSN
1097-0142
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenocarcinomaAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsBiliary Tract NeoplasmsCapecitabineDeoxycytidineDisease-Free SurvivalDrug Administration ScheduleFemaleFluorouracilFollow-Up StudiesGallbladder NeoplasmsHumansMaleMiddle AgedSurvival AnalysisTreatment OutcomeGemcitabine